Cargando…

HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost

The development of a preventive vaccine against human immunodeficiency virus (HIV-1) infection is the most efficient method to control the epidemic. The ultimate goal is to develop a vaccine able to induce specific neutralizing, non-neutralizing antibodies and cellular mediated immunity (CMI). Humor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apostólico, Juliana de Souza, Boscardin, Silvia Beatriz, Yamamoto, Márcio Massao, de Oliveira-Filho, Jethe Nunes, Kalil, Jorge, Cunha-Neto, Edecio, Rosa, Daniela Santoro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699765/ https://www.ncbi.nlm.nih.gov/pubmed/26727218 http://dx.doi.org/10.1371/journal.pone.0145637

Ejemplares similares

Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine
por: Apostólico, Juliana de Souza, et al.
Publicado: (2017)

Poly(I:C) Potentiates T Cell Immunity to a Dendritic Cell Targeted HIV-Multiepitope Vaccine
por: Apostólico, Juliana de Souza, et al.
Publicado: (2019)

Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens
por: Crooks, Emma T., et al.
Publicado: (2021)

Prime-boost with Chikungunya virus E2 envelope protein combined with Poly (I:C) induces specific humoral and cellular immune responses
por: Amaral, Marcelo Pires, et al.
Publicado: (2021)

Heterologous Prime-Boost Combinations Highlight the Crucial Role of Adjuvant in Priming the Immune System
por: Ciabattini, Annalisa, et al.
Publicado: (2018)

Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity
por: Coirada, Fernanda Caroline, et al.
Publicado: (2023)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base
por: Corrigan, Angela R., et al.
Publicado: (2021)

Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting
por: Cheng, Cheng, et al.
Publicado: (2019)

Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells
por: Lunardelli, Victória Alves Santos, et al.
Publicado: (2023)

Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron
por: Bottero, Daniela, et al.
Publicado: (2023)

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates
por: Chakrabarti, BK, et al.
Publicado: (2012)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Antibody responses after intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation
por: Cranage, Martin P., et al.
Publicado: (2011)

Time-dependent contraction of the SARS-CoV-2–specific T-cell responses in convalescent individuals
por: Fernandes, Edgar Ruz, et al.
Publicado: (2022)

Antibody response induced by the boost overdose during COVID-19 heterologous prime-boost vaccination strategy
por: Raposo, Francisco, et al.
Publicado: (2021)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
por: Li, Chong, et al.
Publicado: (2020)

Heterologous prime-boost: an important candidate immunization strategy against Tembusu virus
por: Pan, Yuting, et al.
Publicado: (2020)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
por: Chapman, Ros, et al.
Publicado: (2021)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
por: Gelanew, Tesfaye, et al.
Publicado: (2023)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro
por: Ozorowski, Gabriel, et al.
Publicado: (2018)

ZIKV-envelope proteins induce specific humoral and cellular immunity in distinct mice strains
por: Lunardelli, Victória Alves Santos, et al.
Publicado: (2022)

Similarities and differences between native HIV-1 envelope glycoprotein trimers and stabilized soluble trimer mimetics
por: Torrents de la Peña, Alba, et al.
Publicado: (2019)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
por: Brown, Scott A., et al.
Publicado: (2010)

Revival of the heterologous prime‐boost technique in COVID‐19: An outlook from the history of outbreaks
por: Siddiqui, Amna, et al.
Publicado: (2022)

Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates
por: Bolton, Diane L., et al.
Publicado: (2012)

Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice
por: Pflumm, Dominik, et al.
Publicado: (2023)

Intranasal Liposomal Formulation of Spike Protein Adjuvanted with CpG Protects and Boosts Heterologous Immunity of hACE2 Transgenic Mice to SARS-CoV-2 Infection
por: Russo, Momtchilo, et al.
Publicado: (2023)

Improving the immunogenicity of HIV-1 envelope trimer vaccines
por: Sanders, Rogier W
Publicado: (2011)

Envelope Glycoprotein Trimers as HIV-1 Vaccine Immunogens
por: Sattentau, Quentin J.
Publicado: (2013)

Assessing immunogenicity barriers of the HIV-1 envelope trimer
por: Maliqi, Liridona, et al.
Publicado: (2023)

Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
por: Torrents de la Peña, Alba, et al.
Publicado: (2018)

Adjuvants: Classification, Modus Operandi, and Licensing
por: Apostólico, Juliana de Souza, et al.
Publicado: (2016)

Accelerated heterologous prime-boost adenovirus vector-based SIV vaccine in neonatal rhesus monkeys
por: Liu, J, et al.
Publicado: (2012)

Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8(+) T Cell Responses
por: Ring, Sandra S., et al.
Publicado: (2020)

Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse
por: Guo, Qianqian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v9clqmrfq34sj3fj17jjg7vabi